Psych Meds

0.0(0)
Studied by 18 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/59

flashcard set

Earn XP

Description and Tags

60 Terms

1
New cards
alprazolam (Xanax)
Category: benzodiazepine

Therapeutic Effects: decreases anxiety (anxiolytic), sedation (safety issues), anticonvulsive, muscle relaxation (asthenia)

ADE: addiction, excessive drowsiness

Drug Interactions: alcohol (Hx of ETOH abuse increases risk of BZ abuse)

Patient Education: taper off slowly, do not increase dose without consult, caution with activity (e.g. driving), eliminate stimulants (caffeine)
2
New cards
lorazepam (Ativan)
Category: benzodiazepine

Therapeutic Uses: decreases anxiety (anxiolytic), sedation, anticonvulsive, muscle relaxation (asthenia), med-induced movement disorders; ETOH withdrawal

ADE: addiction, excessive drowsiness (safety issues); akathisia, dystonia

Drug Interactions: alcohol (Hx of ETOH abuse increases risk of BZ abuse)

Patient Education: taper off slowly, do not increase dose without consult, caution with activity (e.g. driving), eliminate stimulants (caffeine)
3
New cards
oxazepam (Serax)
Category: benzodiazepine

Therapeutic Uses: decreases anxiety (anxiolytic), sedation, anticonvulsive, muscle relaxation (asthenia); ETOH withdrawal

ADE: addiction, excessive drowsiness (safety issues)

Drug Interactions: alcohol (Hx of ETOH abuse increases risk of BZ abuse)

Patient Education: taper off slowly, do not increase dose without consult, caution with activity (e.g. driving), eliminate stimulants (caffeine)
4
New cards
diazepam (Valium)
Category: benzodiazepine

Therapeutic Effects: decreases anxiety (anxiolytic), sedation, anticonvulsive, muscle relaxation (asthenia); ETOH withdrawal

Drug Interactions: alcohol (Hx of ETOH abuse increases risk of BZ abuse)

Patient Education: taper off slowly, do not increase dose without consult, caution with activity (e.g. driving), eliminate stimulants (caffeine)
5
New cards
chlordiazepoxide (Librium)
Category: benzodiazepine

Therapeutic Uses: decreases anxiety (anxiolytic), sedation, anticonvulsive, muscle relaxation (asthenia), alcohol withdrawal

ADE: addiction, excessive drowsiness (safety issues)

Drug Interactions: alcohol (Hx of ETOH abuse increases risk of BZ abuse)

Patient Education: taper off slowly, do not increase dose without consult, caution with activity (e.g. driving), eliminate stimulants (caffeine)
6
New cards
clonazepam (Klonopin)
Category: benzodiazepine

Therapeutic Uses: decreases anxiety (anxiolytic), sedation, anticonvulsive, muscle relaxation (asthenia), med-induced movement disorders

ADE: addiction, excessive drowsiness (safety issues); akathisia, dystonia

Drug Interactions: alcohol (Hx of ETOH abuse increases risk of BZ abuse)

Patient Education: taper off slowly, do not increase dose without consult, caution with activity (e.g. driving), eliminate stimulants (caffeine)
7
New cards
trazodone (Desyrel)
Category: Non-benzodiazepine anxiolytic/hypnotic

Therapeutic Effects: treats anxiety (anxiolytic), depression, insomnia; augmenting agent

ADE: carryover sedation, ataxia, intoxicated-like feeling
8
New cards
buspirone (BuSpar)
Category: non-benzodiazepine anxiolytic

MoA: serotonin 1A partial agonist

Therapeutic Effects: stabilizes serotonin (takes longer)

Patient Education: absorption affected by food- consistent administration with/without food
9
New cards
hydroxyzine (Atarax, Vistaril)
Category: non-benzodiazepine anxiolytic, antihistamine, hypnotic
10
New cards
prazosin (Minipress)
Category: non-benzodiazepine anxiolytic, antihypertensive

MoA: alpha 1 adrenergic blocker

Therapeutic Effects: reduces severity and frequency of PTSD nightmares
11
New cards
clonidine (Catapres)
Category: non-benzodiazepine anxiolytic, antihypertensive

MoA: alpha 2 agonist

Therapeutic Effects: reduces autonomic symptoms (e.g. palpitations, sweating)
12
New cards
propanolol (Inderal)
Category: non-benzodiazepine anxiolytic, antihypertensive

MoA: beta blocker

Therapeutic Uses: helps with social/performance anxiety (reduces HR, hand tremors, quivering voice), med-induced movement disorders
13
New cards
zolpidem (Ambien)
Category: non-benzodiazepine hypnotic (Z-drug)

Therapeutic Effects: short term tx for insomnia

ADE: sedation, dizziness, ataxia, dose-dependent amnesia, nervousness, hallucinations (rare)

Drug Interactions: absorbs slower with food

Patient Education: clearance slightly lower in women, take on empty stomach
14
New cards
zaleplon (Sonata)
Category: non-benzodiazepine hypnotic (Z-drug)

Therapeutic Effects: short term tx for insomnia

ADE: sedation, dizziness, ataxia, dose-dependent amnesia, nervousness, hallucinations (rare)

Drug Interactions: absorbs slower with food

Patient Education: take on empty stomach
15
New cards
eszopiclone (Lunesta)
Category: non-benzodiazepine hypnotic (Z-drug)

Therapeutic Effects: longer term tx for insomnia

ADE: sedation, dizziness, ataxia, dose-dependent amnesia, nervousness, hallucinations (rare)

Drug Interactions: absorbs slower with food

Patient Education: unpleasant taste (can take with food?)
16
New cards
diphenhydramine (Benadryl)
Category: non-benzodiazepine hypnotic, antihistamine, anticholinergic

Uses: occasional sleeplessness, antiparkinsonism, drug-induced parkinsonism

ADE: akinesia, dystonia, pseudo-pk
17
New cards
citalopram (Celexa)
Category: non-benzodiazepine anxiolytic, SSRI (antidepressant)

MoA: inhibits reuptake of 5HT → increased availability of 5HT

Therapeutic Effects: first-line tx for anxiety/depression

ADE: GI discomfort (n/v/d, weight change), sleep disturbances, sedation, SI!, mania

Patient Education: takes 4-6 weeks to work, increase energy (safety concern), taper do not abruptly withdraw
18
New cards
escitalopram (Lexapro)
Category: non-benzodiazepine anxiolytic, SSRI (antidepressant)

MoA: inhibits reuptake of 5HT → increased availability of 5HT

Therapeutic Effects: first-line tx for anxiety/depression

ADE: GI discomfort (n/v/d, weight change), sleep disturbances, sedation, SI!, mania

Patient Education: takes 4-6 weeks to work, increase energy (safety concern), taper do not abruptly withdraw
19
New cards
sertraline (Zoloft)
Category: non-benzodiazepine anxiolytic, SSRI (antidepressant)

MoA: inhibits reuptake of 5HT → increased availability of 5HT

Therapeutic Effects: first-line tx for anxiety/depression

ADE: GI discomfort (n/v/d, weight change), sleep disturbances, sedation, SI!, mania

Patient Education: takes 4-6 weeks to work, increase energy (safety concern), taper do not abruptly withdraw
20
New cards
fluoxetine (Prozac)
Category: non-benzodiazepine anxiolytic, SSRI (antidepressant)

MoA: inhibits reuptake of 5HT → increased availability of 5HT

Therapeutic Effects: first-line tx for anxiety/depression

ADE: GI discomfort (n/v/d, weight change), sleep disturbances, sedation, SI!, mania

Patient Education: takes 4-6 weeks to work, increase energy (safety concern), taper do not abruptly withdraw
21
New cards
paroxetine (Paxil)
Category: non-benzodiazepine anxiolytic, SSRI (antidepressant)

MoA: inhibits reuptake of 5HT → increased availability of 5HT

Therapeutic Effects: first-line tx for anxiety/depression

ADE: GI discomfort (n/v/d, weight change), sleep disturbances, sedation, SI!, mania

Patient Education: takes 4-6 weeks to work, increase energy (safety concern), taper do not abruptly withdraw
22
New cards
fluvoxamine (Luvox)
Category: non-benzodiazepine anxiolytic, SSRI (antidepressant)

MoA: inhibits reuptake of 5HT → increased availability of 5HT

Therapeutic Effects: first-line tx for anxiety/depression

ADE: GI discomfort (n/v/d, weight change), sleep disturbances, sedation, SI!, mania

Patient Education: takes 4-6 weeks to work, increase energy (safety concern), taper do not abruptly withdraw
23
New cards
amitriptyline (Elavil)
Category: tricyclic antidepressant (TCA)

MoA: potentiates norepinephrine, dopamine, and serotonin in CNS

Therapeutic Effects: mood elevation, increased appetite

ADE: anticholinergic effects (blurred vision, dry eyes, cardiac arrhythmia), antihistamine (sedation/drowsiness or insomnia, weight gain), antiadrenergic (orthostatic hypotension, dizziness), cardiac effects (tachycardia, arrhythmia), seizures

Contraindications: acute MI recovery

Drug Interactions: other antidepressants (MAOIs\*), other CNS stimulants (masks suicidal tendencies), LETHAL IN OVERDOSE (non-refillable, no more than 1 week)
24
New cards
doxepin (Sinequan)
Category: tri/tetracyclic antidepressant (TCA)

MoA: potentiates norepinephrine, dopamine, and serotonin in CNS

Therapeutic Effects: mood elevation, increased appetite

ADE: anticholinergic effects (blurred vision, dry eyes, cardiac arrhythmia), antihistamine (sedation/drowsiness or insomnia, weight gain), antiadrenergic (orthostatic hypotension, dizziness), cardiac effects (tachycardia, arrhythmia), seizures

Contraindications: acute MI recovery

Drug Interactions: other antidepressants (MAOIs\*), other CNS stimulants (masks suicidal tendencies), LETHAL IN OVERDOSE (non-refillable, no more than 1 week)
25
New cards
imipramine (Tofranil)
Category: tri/tetracyclic antidepressant (TCA)

MoA: potentiates norepinephrine, dopamine, and serotonin in CNS

Therapeutic Effects: mood elevation, increased appetite

ADE: anticholinergic effects (blurred vision, dry eyes, cardiac arrhythmia), antihistamine (sedation/drowsiness or insomnia, weight gain), antiadrenergic (orthostatic hypotension, dizziness), cardiac effects (tachycardia, arrhythmia), seizures

Contraindications: acute MI recovery

Drug Interactions: other antidepressants (MAOIs\*), other CNS stimulants (masks suicidal tendencies), LETHAL IN OVERDOSE (non-refillable, no more than 1 week)
26
New cards
clomipramine (Anafranil)
Category: tri/tetracyclic antidepressant (TCA)

MoA: potentiates norepinephrine, dopamine, and serotonin in CNS

Therapeutic Effects: mood elevation, increased appetite

ADE: anticholinergic effects (blurred vision, dry eyes, cardiac arrhythmia), antihistamine (sedation/drowsiness or insomnia, weight gain), antiadrenergic (orthostatic hypotension, dizziness), cardiac effects (tachycardia, arrhythmia), seizure

Contraindications: acute MI recovery

Drug Interactions: other antidepressants (MAOIs\*), other CNS stimulants (masks suicidal tendencies), LETHAL IN OVERDOSE (non-refillable, no more than 1 week)
27
New cards
nortriptyline (Pamelor)
Category: tri/tetracyclic antidepressant (TCA)

MoA: potentiates norepinephrine, dopamine, and serotonin in CNS

Therapeutic Effects: mood elevation, increased appetite

ADE: anticholinergic effects (blurred vision, dry eyes, cardiac arrhythmia), antihistamine (sedation/drowsiness or insomnia, weight gain), antiadrenergic (orthostatic hypotension, dizziness), cardiac effects (tachycardia, arrhythmia), seizures

Contraindications: acute MI recovery

Drug Interactions: other antidepressants (MAOIs\*), other CNS stimulants (masks suicidal tendencies), LETHAL IN OVERDOSE (non-refillable, no more than 1 week)
28
New cards
desipramine (Norpramin)
Category: tri/tetracyclic antidepressant (TCA)

MoA: potentiates norepinephrine, dopamine, and serotonin in CNS

Therapeutic Effects: mood elevation, increased appetite

ADE: anticholinergic effects (blurred vision, dry eyes, cardiac arrhythmia), antihistamine (sedation/drowsiness or insomnia, weight gain), antiadrenergic (orthostatic hypotension, dizziness), cardiac effects (tachycardia, arrhythmia), seizures

Contraindications: acute MI recovery

Drug Interactions: other antidepressants (MAOIs\*), other CNS stimulants (masks suicidal tendencies), LETHAL IN OVERDOSE (non-refillable, no more than 1 week)
29
New cards
phenelzine (Nardil)
Category: monoamine oxidase inhibitor (MAOI)

MoA: inhibition of MAO enzyme, increases levels of dopamine, norepinephrine, and serotonin

Therapeutic Effects: antidepressant

ADE: anticholinergic effects (dry mouth, blurred vision, urinary retention), insomnia, HA, increased liver enzymes, orthostatic hypotension, weight gain, peripheral edema, sexual dysfunction

Drug Interactions: other antidepressants, opioids, antihypertensives, foods high in tyrosine/tyramine! (aged cheese, aged/smoked/pickled/cured meat, aged/fermented soy/yeast, overripe fruit)

Patient Education: drug interactions can cause serotonin syndrome or hypertensive crisis, monitor BP, avoid tyramine 2 weeks after d/c
30
New cards
tranylcypromine (Parnate)
Category: monoamine oxidase inhibitor (MAOI)

MoA: inhibition of MAO enzyme, increases levels of dopamine, norepinephrine, and serotonin

Therapeutic Effects: antidepressant

ADE: anticholinergic effects (dry mouth, blurred vision, urinary retention), insomnia, HA, increased liver enzymes, orthostatic hypotension, weight gain, peripheral edema, sexual dysfunction

Drug Interactions: other antidepressants, opioids, antihypertensives, foods high in tyrosine/tyramine! (aged cheese, aged/smoked/pickled/cured meat, aged/fermented soy/yeast, overripe fruit)

Patient Education: drug interactions can cause serotonin syndrome or hypertensive crisis, monitor BP, avoid tyramine 2 weeks after d/c
31
New cards
isocarboxazid (Marplan)
Category: monoamine oxidase inhibitor (MAOI)

MoA: inhibition of MAO enzyme, increases levels of dopamine, norepinephrine, and serotonin

Therapeutic Effects: antidepressant

ADE: anticholinergic effects (dry mouth, blurred vision, urinary retention), insomnia, HA, increased liver enzymes, orthostatic hypotension, weight gain, peripheral edema, sexual dysfunction

Drug Interactions: other antidepressants, opioids, antihypertensives, foods high in tyrosine/tyramine! (aged cheese, aged/smoked/pickled/cured meat, aged/fermented soy/yeast, overripe fruit)

Patient Education: drug interactions can cause serotonin syndrome or hypertensive crisis, monitor BP, avoid tyramine 2 weeks after d/c
32
New cards
selegiline (Eldepryl)
Category: monoamine oxidase inhibitor (MAOI)

MoA: inhibition of MAO enzyme, increases levels of dopamine, norepinephrine, and serotonin

Therapeutic Effects: antidepressant

ADE: anticholinergic effects (dry mouth, blurred vision, urinary retention), insomnia, HA, increased liver enzymes, orthostatic hypotension, weight gain, peripheral edema, sexual dysfunction

Drug Interactions: other antidepressants, opioids, antihypertensives, foods high in tyrosine/tyramine! (aged cheese, aged/smoked/pickled/cured meat, aged/fermented soy/yeast, overripe fruit)

Patient Education: drug interactions can cause serotonin syndrome or hypertensive crisis, monitor BP, avoid tyramine 2 weeks after d/c
33
New cards
lithium
Category: mood stabilizer (antimanic)

Therapeutic Effects: bipolar disorder

ADE: weight gain, dysrhythmias, tremors, fatigue, HA, mental dullness, thyroid dysfunction, n/v/d, LITHIUM TOXICITY (severe >2.5 mEq/L: convulsions, decreased urine, renal failure, death)

Drug Interactions: diuretics, NSAIDs, table salt, hormonal birth control (less effective)

Patient Education: narrow TI, lab monitoring (thyroid, renal, serum plasma: 0.6-1.2 mEq/L), consistent sodium intake (do not decrease → increases lithium), serum lithium 12 hr after every dose
34
New cards
valproate/divalproex (Depakote)
Category: mood stabilizer (anticonvulsant)

MoA: enhances GABA

ADE: n/v, hair loss, sedation/drowsiness, weight gain, hepatotoxicity, thrombocytopenia

Therapeutic Serum Level: 45-125 mcg/mL

Patient Education: monitor CBC (platelets) & LFT, lamotrigine levels may increase
35
New cards
carbamazepine (Tegretol)
Category: mood stabilizer (anticonvulsant)

MoA: mediates Na & Ca; reduces release of glutamate

ADE: aplastic anemia, agranulocytosis, SJS

Therapeutic Serum Level: 6-12mcg/mL

Patient Education: monitor CBC, LFT, RFT, TFT
36
New cards
lamotrigine (Lamictal)
Category: mood stabilizer (anticonvulsant)

MoA: modulates Na channels; decreases glutamate release

ADE: less sedation/drowsiness, weight gain; SJS
37
New cards
gabapentin (Neurontin)
Category: anticonvulsant

Therapeutic Uses: neuropathic pain, seizures, migraines, BPD (most use off-label)

ADE: dizziness, drowsiness, peripheral edema, renal toxicity
38
New cards
chlorpromazine (Thorazine)
Category: antipsychotic (typical, 1st gen)

MoA: blocks dopamine receptors in the brain

Therapeutic Uses: schizophrenia, BPD, delusional disorders

ADE: additive effects with other CNS depressants, extrapyramidal effects (low), anticholinergic effects (moderate), sedation/drowsiness (high), hypotension/tachycardia, photosensitivity, teratogenic, ORTHOSTATIC HYPOTENSION

Contraindications: pregnancy (category C)
39
New cards
thioridazine (Mellaril)
Category: antipsychotic (typical, 1st gen)

MoA: blocks dopamine receptors

Therapeutic Uses: schizophrenia (positive symptoms)

ADE: SEDATION, eps (low), ORTHOSTATIC HYPOTENSION, ANTICHOLINERGIC EFFECTS
40
New cards
perphenazine (Trilafon)
Category: antipsychotic (typical, 1st gen)

MoA: blocks dopamine receptors

Therapeutic Uses: schizophrenia (positive symptoms)

ADE: sedation (low), EPS (high), orthostatic hypotension (moderate), anticholinergic effects (low)
41
New cards
thiothixene (Navane)
Category: antipsychotic (typical, 1st gen)

MoA: blocks dopamine receptors

Therapeutic Uses: schizophrenia (positive symptoms)

ADE: sedation (low), EPS (high), orthostatic hypotension (low), anticholinergic effects (low)
42
New cards
fluphenazine (Prolixin)
Category: antipsychotic (typical, 1st gen); available as LAI

MoA: blocks dopamine receptors

Therapeutic Uses: schizophrenia (positive symptoms)

ADE: sedation (low), EPS (very high), orthostatic hypotension (low), anticholinergic effects (low)
43
New cards
haloperidol (Haldol)
Category: antipsychotic (typical, 1st gen); available as LAI

Subcategory: dopamine antagonist

MoA: blocks dopamine receptors in the brain

Therapeutic Uses: schizophrenia, BPD, delusional disorders, nausea

ADE: additive effects with other CNS depressants, extrapyramidal effects (very high), anticholinergic effects, sedation/drowsiness, hypotension/tachycardia, photosensitivity, teratogenic

Contraindications: pregnancy (category C)
44
New cards
clozapine (Clozaril)
Category: antipsychotic (atypical, 2nd gen)

MoA: dopamine antagonist, affects serotonin receptors

Therapeutic Uses: treatment-resistant schizophrenia, improves cognitive and negative symptoms

ADE: SEDATION, eps (very low), ORTHOSTATIC HYPOTENSION, ANTICHOLINERGIC EFFECTS, metabolic changes/weight gain, seizures, NMS, myocarditis/cardiomyopathy, tachycardia

Pt Edu: risk of severe neutropenia (agranulocytosis) → “no blood, no drug”, monitor ANC (normal >1500/microL)

* mild neutropenia (1000 to 1499/microL)
* continue tx
* increase monitoring frequency to 3x/week
* moderate neutropenia (500 to 999/microL)
* interrupt clozapine tx
* daily monitoring until ANC >1000 microL, then 3x/week until ANC > 1500 microL
* resume treatment after ANC > 1000 microL
* hematology consultation required
* severe neutropenia (< 500/microL)
* interrupt clozapine tx
* daily monitoring until ANC > 1000 microL, then 3x/week until ANC > 1500 microL
* hematology consultation required
* rechallenge only if benefits outweigh risks
45
New cards
olanzapine (Zyprexa)
Category: antipsychotic (atypical, 2nd gen)

MoA: dopamine antagonists, serotonin receptors

Therapeutic Uses: schizophrenia (improves negative and cognitive symptoms)

ADE: sedation (moderate), eps, orthostatic hypotension (moderate), anticholinergic effects (moderate)
46
New cards
risperidone (Risperdal)
Category: antipsychotic (atypical, 2nd gen)

MoA: dopamine antagonists, serotonin receptors

Therapeutic Uses: schizophrenia (improves negative and cognitive symptoms)

ADE: sedation (low), eps (mild), orthostatic hypotension (moderate), anticholinergic effects (very low)
47
New cards
paliperidone (Invega)
Category: antipsychotic (atypical, 2nd gen)

MoA: dopamine antagonists, serotonin receptors

Therapeutic Uses: schizophrenia (improves negative and cognitive symptoms)
48
New cards
quetiapine (Seroquel)
Category: antipsychotic (atypical, 2nd gen)

MoA: dopamine antagonists, serotonin receptors

Therapeutic Uses: schizophrenia (improves negative and cognitive symptoms)

ADE: sedation (moderate), eps (low), orthostatic hypotension (moderate), anticholinergic effects (mild)
49
New cards
ziprasidone (Geodon)
Category: antipsychotic (atypical, 2nd gen)

MoA: dopamine antagonists, serotonin receptors

Therapeutic Uses: schizophrenia (improves negative and cognitive symptoms)

ADE: sedation (low), eps (low), orthostatic hypotension (mild), anticholinergic effects (mild)
50
New cards
aripiprazole (Abilify)
Category: antipsychotic (atypical, 2nd gen)

MoA: dopamine antagonists, serotonin receptors

Therapeutic Uses: schizophrenia (improves negative and cognitive symptoms)

ADE: sedation (low), eps (low), orthostatic hypotension (low-mild), anticholinergic effects (low-mild)
51
New cards
lurasidone (Latuda)
Category: antipsychotic (atypical, 2nd gen)

MoA: dopamine antagonists, serotonin receptors

Therapeutic Uses: schizophrenia (improves negative and cognitive symptoms)

ADE: sedation (moderate), EPS (high)
52
New cards
benztropine (Cogentin)
Category: Anticholinergic

Use: med-induced movement disorders

MoA: competes with Ach, anticholinergic effect

Therapeutic Effects: Parkinsonism symptoms

ADE: CNS depression (safety, worsening of mental problems); akinesia, akathisia, dystonia, pseudo-pk
53
New cards
trihexyphenidyl (Artane)
Category: anticholinergic

Use: med-induced movement disorders

ADE: akinesia, akathisia, dystonia, pseudo-pk
54
New cards
amantadine (Symmetrel)
Category: non-anticholinergic/other

Use: med-induced movement disorders
55
New cards
naltrexone (ReVia)
Category: SUD drug

Use: diminishes opiate cravings

MoA: opiate antagonists

ADE: n/v, decreased appetite, dizziness, anxiety, hepatotoxicity

Pt Edu: obtain LFTs before and monitor periodically
56
New cards
acamprosate (Campral)
Category: SUD drug

Use: diminishe ETOH cravings

MoA: similar to GABA

ADE: diarrhea, HA, decreased libido

Pt Edu: no organ toxicity, fewer ADEs
57
New cards
disulfiram (Antabuse)
Category: SUD drug

Use: ETOH aversion treatment

MoA: causes buildup of toxic substance in the body by interrupting ETOH metabolism when using ETOH

ADE: metallic aftertaste, dermatitis, elevated LFTs, mood swings, hepatitis, peripheral neuropathy, psychotic rxns

Symptoms if ETOH is taken:

mild (severe HA, n/v, flushing, tachycardia, dyspnea, sweating, chest pain, dizziness, burning sensation in their face & stomach)

severe (RD, CV collapse, convulsion, unconsciousness, death)

Pt Edu: Pt should have motivation to quit, awareness of consequences, informed consent, medical screening; written list of alcohol-containing preparations to avoid (cough medicine, vinegar, mouthwash); read labels carefully, talk to providers, carry a card; do not take 12 hours after drinking; reaction can occur up to 14 days after last dose
58
New cards
thiamine, folate, multivitamin
Category: SUD drugs

Use: ETOH-induced persisting amnestic disorder

Wernicke encephalopathy: ataxia, ophthalmoplegia, confusion, disorientation, inattentiveness, indifference, impairment of short-term memory

Korsakoff’s psychosis/syndrome: anterograde & retrograde amnesia, confabulation, meager, content in conversation, lack of insight, apathy
59
New cards
naloxone (Narcan)
Use: opioid overdose
60
New cards
suboxone (Buprenorphine)
Category: SUD drug

MoA: blocks opioid receptors, long acting

Use: opioid use treatment- suppresses withdrawal symptoms, reduces cravings

Pt Edu: Buprenorphine is an opioid and does result in physical dependence, safer and fewer side effects than methadone, lower abuse potential than methadone

\